Accountable Care Organizations are set to transform the US health market, establishing efficiencies in patient care and physician working. While their impact to date is limited, ACOs ever widening remit as key funding and decision-making stakeholders makes them important players in the state and privately funded health market. Are ACOs friends or foes of pharma and how should the industry expand and adapt its stakeholder engagement strategies for best advantage?
Essential ACO Engagement: Mapping New Networks of Influence is essential reading for commercial planners and practitioners. The report is based on the insights and experiences of sales and market access professionals working in US pharma companies and experts working in ACOs see who they are. Packed with insights and actionable information, this study identifies the issues, threats and opportunity areas that ACOs present to the pharma industry.
“If pharma doesn’t work with the ACOs and show their product is of value, they won't prescribe it. The physician is at risk now, so companies have to demonstrate value for their product.”
Reasons to Purchase
Answering key questions
ACO Structure: There are 6 types of ACO – what are they, how do they differ from each other and why is it important to know?
ACO Challenges: What are the challenges ACOs face and what role might industry play in overcoming them?
Next Generation ACOs: How do the “next generation” ACOs differ from the pioneer ACOs and what should industry know about them?
Data exchange? Industry can support its value proposition with real world data, while ACOs’ access to electronic medical records brings a wider perspective – could data be a platform for partnership?
Drivers for change: What are the ACO drivers and priorities that could impact pharma sales?
Drug Pricing: How might ACO value for money considerations impact drug prices?
Engagement: In future, industry will have to engage with a wider group of stakeholders – what are the implications for resourcing and the structure of sales and market access teams?
With this report you will be able to
Learn the impact ACOs are currently having and know how “next generation” ACOs will differ
Understand the patient care and cost saving drivers and priorities that are shaping ACO activity
Know how and why ACOs will eventually influence prescribing and formulary decisions and develop value-based propositions that meet ACO and patient needs
Identify the areas of mutual interest and collaboration between ACO and industry and formulate strategies for engagement
Use the insights to review your current sales and market access resources and plan for wider stakeholder engagement in the future
Key topics explored
With an agenda for improving patient outcomes while reducing cost, ACOs are now part of the health landscape and will grow in importance.
ACO organization varies widely and reflects the patient population needs it serves – this is a challenge for industry in establishing engagement and communication policies.
Industry has been slow to accommodate ACOs in their stakeholder strategies, but as ACOs become more influential pharma must ensure the appropriate resource to engage effectively.
Long-term relationships with KOLs may become less valuable as decision making moves to ACO teams and committees.
Patient awareness of ACOs is low and the model of integrated care alien to US society: what communication issues does this raise for industry.
Jeff Carbone, VP, The Bloc Value Builders
Les Duncan, Vice President of Accountable Care Initiatives, River Health ACO
Jeb Dunkelberger, Executive Director, Accountable Care Services
Lloyd J. Guthrie, MBA, Program Manager, Statewide Initiatives, Center for Improving Value in Health Care
Managed Care Medical Director
Market Access Director, midsize pharmaceutical company
Senior director, global pharmaceutical company
VP Managed Care
What is an Accountable Care Organization?
Essentially, an ACO is a network of doctors and hospitals that shares financial and medical responsibility for providing coordinated care to patients and so limit unnecessary spending. ACOs are characterized by a payment and care delivery model that ties reimbursement for providers to quality metrics and reductions in the total cost of care for a particular population of patients. In essence, providers will receive payment if they are able to deliver outcomes that are shown to reduce overall spending on patient health – and that includes making cost effective medicines choices.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.